Glen Eagle Advisors, LLC Amgen Inc Transaction History

Glen Eagle Advisors, LLC

$593 Billion
Q3 2024

A detailed history of Glen Eagle Advisors, LLC transactions in Amgen Inc stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 1,858 shares of AMGN stock, worth $547,236. This represents 0.1% of its overall portfolio holdings.

Number of Shares

1,858

Previous 1,956 5.01%

Holding current value

$547,236

Previous $611 Million 2.04%

% of portfolio

0.1%

Previous 0.11%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$309.38 - $337.38 $30,319 - $33,063	-98 Reduced 5.01%	1,858 $599 Million
Q2 2024 Aug 14, 2024	SELL	$262.75 - $319.31 $195,486 - $237,566	-744 Reduced 27.56%	1,956 $611 Million
Q1 2024 Jul 03, 2024	BUY	$268.87 - $324.56 $497,678 - $600,760	1,851 New	1,851 $526 Million
Q4 2023 Aug 13, 2024	SELL	$255.7 - $288.46 $32,473 - $36,634	-127 Reduced 6.42%	1,850 $533 Million
Q3 2023 Aug 13, 2024	SELL	$218.65 - $271.46 $10,713 - $13,301	-49 Reduced 2.42%	1,977 $531 Million
Q2 2023 Aug 13, 2024	BUY	$214.27 - $253.37 $857 - $1,013	4 Added 0.2%	2,026 $450 Million
Q1 2023 Aug 13, 2024	BUY	$225.79 - $275.2 $1,580 - $1,926	7 Added 0.35%	2,022 $489 Million
Q4 2022 Aug 13, 2024	BUY	$229.03 - $291.01 $15,115 - $19,206	66 Added 3.39%	2,015 $529 Million
Q3 2022 Aug 13, 2024	SELL	$224.46 - $253.15 $897 - $1,012	-4 Reduced 0.2%	1,949 $439 Million
Q2 2022 Aug 13, 2024	SELL	$230.71 - $256.74 $1,614 - $1,797	-7 Reduced 0.36%	1,953 $475 Million
Q1 2022 Aug 13, 2024	SELL	$219.27 - $242.57 $42,538 - $47,058	-194 Reduced 9.01%	1,960 $474 Million
Q4 2021 Aug 13, 2024	SELL	$198.88 - $227.6 $88,700 - $101,509	-446 Reduced 17.15%	2,154 $485 Million
Q3 2021 Aug 13, 2024	SELL	$212.27 - $248.7 $9,976 - $11,688	-47 Reduced 1.78%	2,600 $553 Million
Q2 2021 Aug 13, 2024	SELL	$233.58 - $259.14 $12,613 - $13,993	-54 Reduced 2.0%	2,647 $645 Million
Q1 2021 Aug 13, 2024	BUY	$221.91 - $258.6 $4,216 - $4,913	19 Added 0.71%	2,701 $672 Million
Q4 2020 Aug 13, 2024	BUY	$216.38 - $257.67 $179,811 - $214,123	831 Added 44.89%	2,682 $617 Million
Q3 2020 Aug 13, 2024	SELL	$234.65 - $260.95 $5,631 - $6,262	-24 Reduced 0.86%	2,762 $702 Million
Q2 2020 Aug 13, 2024	BUY	$197.81 - $242.74 $1,582 - $1,941	8 Added 0.29%	2,786 $657 Million
Q1 2020 Aug 13, 2024	SELL	$182.24 - $241.7 $14,396 - $19,094	-79 Reduced 2.77%	2,778 $563 Million
Q4 2019 Aug 13, 2024	SELL	$189.21 - $243.2 $5,676 - $7,296	-30 Reduced 1.04%	2,857 $689 Million
Q2 2019 Aug 13, 2024	BUY	$166.7 - $195.41 $6,834 - $8,011	41 Added 1.44%	2,887 $532 Million
Q1 2019 Aug 13, 2024	BUY	$180.87 - $203.88 $179,965 - $202,860	995 Added 53.75%	2,846 $541 Million
Q4 2018 Aug 13, 2024	BUY	$178.4 - $208.25 $8,920 - $10,412	50 Added 1.83%	2,783 $542 Million
Q3 2018 Aug 13, 2024	BUY	$185.29 - $208.89 $1,482 - $1,671	8 Added 0.29%	2,733 $566 Million
Q2 2018 Aug 13, 2024	SELL	$166.05 - $186.51 $61.8 Million - $69.4 Million	-372,004 Reduced 99.27%	2,725 $503 Million
Q1 2018 Aug 14, 2024	BUY	$169.43 - $198.0 $143,846 - $168,102	849 Added 45.87%	2,700 $460 Million
Q1 2018 Aug 13, 2024	BUY	$169.43 - $198.0 $63.4 Million - $74.1 Million	374,249 Added 77968.54%	374,729 $460 Million
Q4 2017 Aug 13, 2024	SELL	$168.79 - $188.59 $363,911 - $406,600	-2,156 Reduced 81.79%	480 $83.5 Million
Q3 2017 Aug 13, 2024	BUY	$167.29 - $191.0 $131,322 - $149,935	785 Added 42.41%	2,636 $491 Million
Q2 2017 Aug 12, 2024	BUY	N/A	19 Added 4.99%	400 $68.9 Million
Q1 2017 Aug 12, 2024	BUY	N/A	46 Added 13.73%	381 $62.5 Million
Q4 2016 Aug 12, 2024	SELL	N/A	-1,516	335 $49 Million

Others Institutions Holding AMGN

# of Institutions

3,122

Shares Held

410M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $158B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Glen Eagle Advisors, LLC with notifications on news.

Account

Glen Eagle Advisors, LLC Amgen Inc Transaction History